Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12157547 | 0.96 | ADORA2A (0.39) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL12857099 | 0.85 | CYP1A2 (0.38) | ADORA2AADORA1ADORA2BADORA3CA1 | |
| Trifluoroacetic Acid SCHEMBL2199183 | 0.85 | S1PR1 (0.35) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL13849616 | 0.84 | KCNH3 (0.38) | ADORA2AADORA1ADORA2BADORA3ALDH1A1 | |
| SCHEMBL12157668 | 0.80 | ADORA2A (0.34) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL20801388 | 0.80 | SLC29A1 (0.43) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL20275528 | 0.78 | MAPT (0.33) | TLR7TLR8 | |
| SCHEMBL14224934 | 0.76 | ADORA2A (0.40) | ADORA2AADORA1ADORA2BADORA3TLR7 | |
| SCHEMBL731519 | 0.75 | TLR7 (0.41) | TLR7 | |
| SCHEMBL29977805 | 0.75 | TLR7 (0.41) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2019-02-07 | — | — | US | disclosed |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
| US-9877968-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-9877968-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| EP-3246030-A1 | NOVEL ADENINE DERIVATIVES | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2320905-B1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20160228445-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160228445-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2016-08-11 | — | — | US | disclosed |
| US-9346806-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2016-05-24 | — | — | US | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2010018130-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018131-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018134-A1 | NOVEL ADENINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018133-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008101867-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131458-A1 | Compounds | LTC4S, LTB4R2, LTB4R | ADORA2A 907/4885ADORA1 694/4885ADORA2B 494/4885 |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | LTC4S, STING1, LTB4R2 | ADORA2A 54/4885ADORA1 39/4885ADORA2B 33/4885 |
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | ADORA2A 78/4885ADORA1 32/4885ADORA2B 46/4885 |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | ADORA2A 78/4885ADORA1 32/4885ADORA2B 46/4885 |
| US-20100075995-A1 | COMPOUNDS | IFNG, IRF3, IFNAR1 | ADORA2A 1039/4885ADORA1 439/4885ADORA2B 631/4885 |
| US-20160228445-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | ADORA2A 78/4885ADORA1 32/4885ADORA2B 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.